| dbo:abstract
|
- ميلاتوزوماب هو جسم مضاد وحيد النسيلة مرتبط بدوكسوروبيسين بدأت المرحلتين الأولى والثانية من التجارب السريرية لاستخدامه في علاج الورم النقوي المتعدد وأورام الدم الأخرى. (ar)
- Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia. Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA). (en)
- Milatuzumab è un anticorpo monoclonale umanizzato studiato per il trattamento del mieloma multiplo e di altre neoplasie ematologiche. Questo farmaco è stato sviluppato da , Inc. Il farmaco è chimicamente legato alla doxorubicina per formare un coniugato anticorpo-farmaco per il trattamento di una recidiva del mieloma multiplo. Attualmente è in corso una sperimentazione clinica di fase I/II. IL target molecolare è l'antigene: . (it)
|
| dbo:casNumber
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 6577 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:h
| |
| dbp:kegg
| |
| dbp:mabType
| |
| dbp:n
| |
| dbp:o
| |
| dbp:s
| |
| dbp:source
| |
| dbp:target
| |
| dbp:type
| |
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- ميلاتوزوماب هو جسم مضاد وحيد النسيلة مرتبط بدوكسوروبيسين بدأت المرحلتين الأولى والثانية من التجارب السريرية لاستخدامه في علاج الورم النقوي المتعدد وأورام الدم الأخرى. (ar)
- Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia. Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA). (en)
- Milatuzumab è un anticorpo monoclonale umanizzato studiato per il trattamento del mieloma multiplo e di altre neoplasie ematologiche. Questo farmaco è stato sviluppato da , Inc. Il farmaco è chimicamente legato alla doxorubicina per formare un coniugato anticorpo-farmaco per il trattamento di una recidiva del mieloma multiplo. Attualmente è in corso una sperimentazione clinica di fase I/II. IL target molecolare è l'antigene: . (it)
|
| rdfs:label
|
- ميلاتوزوماب (ar)
- Milatuzumab (it)
- Milatuzumab (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
